Aktion Associates Acquires Acumatica and Legacy Sage Practice From Canadian-based MNP
This acquisition of 500 customers and employees across eight provinces provides Aktion with a launch point to cover the entire Canadian market. "Aktion will use this Sage and Acumatica customer base as a footprint to launch our Infor, Deltek, and Managed Service Provider (MSP) business divisions in
"The decision to transition this part of our business to Aktion reflects MNP's commitment to doing what is best for our clients and our people," said
The new customers will have access to Aktion's complete suite of IT services. Aktion's offerings include specialized network and software engineering, application and industry-specific consulting, and robust cloud and managed services tailored to the unique needs of our focused industries.
About Aktion
Aktion Associates delivers industry-specific and market-leading application solutions to the Architecture & Engineering, Construction, Wholesale Distribution and Manufacturing industries. We couple these application solutions with proven business process transformation skills that deliver the best Net Promoter Scores in the industry for small and medium-size businesses. Our investment in our company-owned cloud and managed services platform is what further allows us to deliver a complete technology solution cost-effectively and efficiently. Visit www.aktion.com.
About MNP LLP
National in scope and local in focus, MNP is one of
View original content to download multimedia:https://www.prnewswire.com/news-releases/aktion-associates-acquires-acumatica-and-legacy-sage-practice-from-canadian-based-mnp-302133794.html
SOURCE Aktion Associates, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
- Binance Coin Price Holds $730 After 1.6M Burn as Buyers Bet Pepeto Can Be the Next BNB
- New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share